secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2026-08-24T12:15:14+00:00
Accession:  0001193125-26-361895
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca gets FDA Fast Track for ERAS-0015 in metastatic pancreatic cancer
------------------------------------------------------------------------

- FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma on Aug 24, 2026.
- FTD may enable accelerated approval, priority review, and rolling review if criteria met.
- Company plans phase 3 trial in pancreatic cancer and two registration-enabling trials in lung cancer.
- FTD does not change approval standards; FDA may later revoke designation or not shorten review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526361895/0001193125-26-361895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312526361895/eras-20260824.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-361895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer